AAAAAA

   
Results: 1-14 |
Results: 14
Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients
Authors: Graff, DW Williamson, KM Pieper, JA Carson, SW Adams, KF Cascio, WE Patterson, JH
Citation: Dw. Graff et al., Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients, J CLIN PHAR, 41(1), 2001, pp. 97-106
Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy
Authors: Shah, MR Hasselblad, V Gheorghiade, M Adams, KF Swedberg, K Califf, RM O'Connor, CM
Citation: Mr. Shah et al., Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy, AM J CARD, 88(9), 2001, pp. 987-993
Which beta-blocker for heart failure?
Authors: Adams, KF
Citation: Kf. Adams, Which beta-blocker for heart failure?, AM HEART J, 141(6), 2001, pp. 884-888
Hemodynamics as surrogate end points for survival in advanced heart failure: An analysis from FIRST
Authors: Shah, MR Stinnett, SS McNulty, SE Gheorghiade, M Zannad, F Uretsky, B Adams, KF Califf, RM O'Connor, CM
Citation: Mr. Shah et al., Hemodynamics as surrogate end points for survival in advanced heart failure: An analysis from FIRST, AM HEART J, 141(6), 2001, pp. 908-914
Understanding the management of heart failure
Authors: Patterson, JH Adams, KF
Citation: Jh. Patterson et Kf. Adams, Understanding the management of heart failure, PHARMACOTHE, 20(5), 2000, pp. 493-494
HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches
Authors: Adams, KF Baughman, KL Dec, WG Elkayam, U Forker, AD Gheorghiade, M Hermann, D Konstam, MA Liu, P Massie, BM Patterson, JH Silver, MA Stevenson, LW Feldman, AM Cohn, JN Francis, GS Greenberg, B Konstam, MA Leier, C Lorell, BH Packer, M Pitt, B Silver, MA Sonnenblick, E Strobeck, J Walsh, R Yusuf, S
Citation: Kf. Adams et al., HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches, PHARMACOTHE, 20(5), 2000, pp. 495-522
Developing clinical practice guidelines for heart failure: Creative process and practice implications
Authors: Adams, KF
Citation: Kf. Adams, Developing clinical practice guidelines for heart failure: Creative process and practice implications, PHARMACOTHE, 20(11), 2000, pp. 379S-384S
Rationale and design of the OPTIME CHF trial: Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure
Authors: Cuffe, MS Califf, RM Adams, KF Bourge, RC Colucci, W Massie, B O'Connor, CM Pina, I Quigg, R Silver, M Robinson, LA Leimberger, JD Gheorghiade, M
Citation: Ms. Cuffe et al., Rationale and design of the OPTIME CHF trial: Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure, AM HEART J, 139(1), 2000, pp. 15-22
Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes
Authors: O'Connor, CM Gattis, WA Zannad, F McNulty, SE Gheorghiade, M Adams, KF Califf, RM McKenna, WJ Soler-Soler, J Swedberg, K
Citation: Cm. O'Connor et al., Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes, EUR J HE FA, 1(1), 1999, pp. 81-88
HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches - Heart Failure Society of America
Authors: Adams, KF Baughman, KL Dec, WG Elkayam, U Forker, AD Gheorghiade, M Hermann, D Konstam, MA Liu, P Massie, BM Patterson, JH Silver, MA Stevenson, LW Feldman, AM Cohn, JN Francis, GS Greenberg, B Konstam, MA Leier, C Lorell, BH Packer, M Pitt, B Silver, MA Sonnenblick, E Strobeck, J Walsh, R Yusuf, S
Citation: Kf. Adams et al., HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches - Heart Failure Society of America, J CARD FAIL, 5(4), 1999, pp. 357-382
Association of body mass, gender and race with heart failure primarily dueto hypertension
Authors: Dunlap, SH Sueta, CA Tomasko, L Adams, KF
Citation: Sh. Dunlap et al., Association of body mass, gender and race with heart failure primarily dueto hypertension, J AM COL C, 34(5), 1999, pp. 1602-1608
Gender differences in survival in advanced heart failure - Insights from the FIRST study
Authors: Adams, KF Sueta, CA Gheorghiade, M O'Connor, CM Schwartz, TA Koch, GG Uretsky, B Swedberg, K McKenna, W Soler-Soler, J Califf, RM
Citation: Kf. Adams et al., Gender differences in survival in advanced heart failure - Insights from the FIRST study, CIRCULATION, 99(14), 1999, pp. 1816-1821
Continuous intravenous dobutamine is associated with an increased risk of death in patients advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)
Authors: O'Connor, CM Gattis, WA Uretsky, BF Adams, KF McNulty, SE Grossman, SH McKenna, WJ Zannad, F Swedberg, K Gheorghiada, M Califf, RM
Citation: Cm. O'Connor et al., Continuous intravenous dobutamine is associated with an increased risk of death in patients advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST), AM HEART J, 138(1), 1999, pp. 78-86
Angiotensin-converting enzyme inhibition and vascular remodeling in coronary artery disease
Authors: Adams, KF
Citation: Kf. Adams, Angiotensin-converting enzyme inhibition and vascular remodeling in coronary artery disease, CORON ART D, 9(10), 1998, pp. 675-684
Risultati: 1-14 |